摘要
目的探讨重组人粒细胞集落刺激因子对噬血细胞综合征患者支持治疗的疗效和安全性。方法回顾分析2013年1月至2015年6月期间应用重组人粒细胞集落刺激因子作为支持治疗的噬血细胞综合征患者105例,观察其4周的生存率、临床指标的变化及不良反应。结果 105例患者中有5例死亡,治疗前后体温、血小板、丙氨酸氨基转移酶、甘油三酯以及铁蛋白均有显著性差异(P<0.05),以上指标在治疗后均有明显的好转。应用重组人粒细胞集落刺激因子期间,常见不良反应为皮肤潮红、骨痛、肌肉酸痛。结论重组人粒细胞集落刺激因子是噬血细胞综合征患者安全有效的支持治疗药物。
Objective To explore the efficacy and safety of application of recombinant human granulocyte colony- stimulating factor in supportive treatment for patients with hemophagocytic syndrome. Methods The clinical data of 105 patients treated with recombinant human granulocyte colony stimulating factor as supportive treatment during January 2013 to June 2015 were retrospectively analyzed. The survival rate,clinical indexes and adverse reactions in 4 weeks were observed. Results Five of 105 patients died. The temperature,serum levels of alanine aminotransferase,triglyceride and ferritin,and platelet count were significantly changed after the treatment,and the difference before and after the treatment was significant（ P〈0. 05）,and above indexes had been significantly improved. During the period of application of recombinant human granulocyte colony- stimulating factor,the common adverse reactions were skin flushing,pain of bone and musclar soreness. Conclusion Recombinant human granulocyte colony- stimulating factor is a safe and effective drug in treatment of patients with hemophagocytic syndrome.
出处
《临床和实验医学杂志》
2016年第9期835-838,共4页
Journal of Clinical and Experimental Medicine
基金
北京市自然科学基金项目(7132087)
国家自然科学基金青年科学基金项目(81401627)
首都医学发展基金(首发2014-4-2025)
北京市科委首都特色项目(Z151100004015172)
北京市科委首都市民健康项目培育(Z131100006813041)
北京市优秀人才资助项目(2013D003034000017)
关键词
噬血细胞综合征
重组人粒细胞集落刺激因子
支持治疗
不良反应
Hemophagocytic syndrome
Recombinant human granulocyte colony-stimulating factor
Supportive treatment
Adverse reactions
